预约演示
更新于：2026-04-12
Propranolol Hydrochloride
盐酸普萘洛尔
更新于：2026-04-12
概要
基本信息
简介盐酸普萘洛尔是一种小分子药物，作用于β-肾上腺素受体，是一种β-肾上腺素受体拮抗剂。它的主要适应症包括高血压、心绞痛、心房颤动、心房早搏复杂性、心动过缓和心动过速。普萘洛尔可以通过阻断β-肾上腺素受体来减少心率和收缩力，降低血压和心脏氧耗。这种药物还可以用于预防偏头痛和手部震颤，以及减轻焦虑和精神失常症状。普萘洛尔的原研组织为阿斯利康，于1966年8月18日获得首次批准。 |
药物类型 小分子化药 |
别名 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol、1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol、beta-Propranolol + [38] |
作用方式 拮抗剂 |
作用机制 β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C16H22ClNO2 |
InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N |
CAS号318-98-9 |
关联
455
项与 盐酸普萘洛尔 相关的临床试验NCT05797662
A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults
NCT07452978
Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence: A Single-Center Randomized Placebo-Controlled Pilot Study
CTIS2025-524194-17-00
EFFICACY OF PROPRANOLOL IN TRAUMATIC BRAIN INJURY PATIENTS ADMITTED TO THE ICU: A PROSPECTIVE, RANDOMIZED, TRIPLE-BLIND STUDY (ProP TBI in ICU)
100 项与 盐酸普萘洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的专利（医药）
登录后查看更多信息
41,875
项与 盐酸普萘洛尔 相关的文献（医药）2026-04-01JOURNAL OF ULTRASOUND IN MEDICINE
Prenatal Ultrasound Diagnosis and Prognostic Analysis of Fetal Congenital Hepatic Hemangioma
Article
作者: Li, Chunying ; Qi, Jun ; Hao, Yu ; Lin, Xiaojuan ; Pei, Jinxia ; Song, Xiaoyu ; Wang, Yilin ; Yang, Yingying
Objectives:
This study investigates the sonographic features, treatment, and prognosis of fetal congenital hepatic hemangioma (CHH), aiming to enhance prenatal diagnostic accuracy and provide insights for standardized management during both the prenatal and postnatal periods.
Methods:
A retrospective analysis was conducted on fetuses diagnosed with CHH by prenatal ultrasound and further confirmed by MRI (magnetic resonance imaging) or CT (computed tomography) between April 2019 and April 2025 at our institution. We analyzed and summarized prenatal and postnatal diagnostic findings, clinical manifestations, management strategies, and clinical outcomes in these patients.
Results:
A total of 14 patients were included, with a median follow‐up of 54 months. The gestational age at diagnosis was 32 ± 6 weeks, and chromosomal analysis revealed normal. Fetal CHH are predominantly solitary lesions (92.9%, 13/14), most commonly located in the right hepatic lobe (64.3%, 9/14). Sonographically, they typically present as well‐defined, hypervascular mixed‐echogenicity masses. In our cohort, commonly observed features included sieve‐like or honeycomb anechoic areas within the lesion. Pulsed Doppler imaging frequently reveals low‐to‐moderate resistance flow spectra. Two fetuses presented with an enlarged cardiothoracic ratio, one with a giant hepatic hemangioma and one with a non‐giant lesion. Additionally, one case of right heart enlargement was observed in a fetus with a giant hepatic hemangioma. One pregnancy was terminated due to poor prognosis secondary to rapid tumor progression in the third trimester; another termination occurred for non‐medical reasons during late gestation, and the remaining 12 pregnancies progressed to live births. Among live‐born infants, 10 underwent active surveillance postnatally, while 2 required interventional therapy due to oral propranolol failure or persistent tumor growth. Ultimately, complete tumor regression occurred in 8 cases (66.7%, 8/12), with a median follow‐up of 24 months. Partial regression in 3 (25.0%, 3/12) and stable disease in 1 (8.3%, 1/12). Additionally, the incidence of postnatal laboratory abnormalities, including hepatic dysfunction, coagulopathy, thyroid disorders, or elevated alpha‐fetoprotein (AFP), was 16.7% (2/12) in live‐born infants.
Conclusion:
While prenatal ultrasound manifestations of fetal CHH demonstrate considerable heterogeneity, features are commonly observed in our cohort. Definitive diagnosis can be achieved in most cases through multimodal imaging combining ultrasound with MRI or CT. While most fetuses with CHH have a favorable prognosis, large tumors may cause severe complications and adverse pregnancy outcomes, warranting regular surveillance. For neonates with small tumors or asymptomatic lesions, active observation is the primary management strategy; pharmacotherapy is indicated for rapidly enlarging or large tumors, with interventional or surgical interventions reserved for pharmacologically refractory cases.
2026-04-01BRAIN & DEVELOPMENT
Cyclic vomiting syndrome
Review
作者: Hikita, Toshiyuki
Cyclic vomiting syndrome (CVS) is characterized by recurrent vomiting episodes. In this study, the mean ages at the onset of symptoms and at the diagnosis of children with cyclic vomiting pattern were 5.7 and 8.0 years, respectively. On average 2.3 years elapsed between the onset and diagnosis, suggesting the difficulty of diagnosing CVS. However, the prevalence of CVS ranges from approximately 0.3% to 2%. Its pathophysiology, prognosis, and natural history need to be further investigated. Various abortive and prophylactic therapies that have been applied in CVS cases were reported. To date, no randomized control study on abortive therapy (i.e., treatment intended to stop a migraine once it starts) for CVS has yet been conducted. Current treatment recommendations are detailed in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) 2025 guidelines for the management of CVS in children. The NASPGHAN 2025 guidelines for the management of CVS in children recommend non-steroidal anti-inflammatory drugs, triptans, ondansetron, aprepitant, and fosaprepitant for acute medicine. The NASPGHAN 2025 guidelines for the management of CVS in children recommend coenzyme Q10, riboflavin, and magnesium as preventive treatments. The recommended medications include propranolol, cyproheptadine, aprepitant, and amitriptyline. The guidelines also recommend not using the antiseizure medications topiramate and valproic acid. However, antiseizure medications are recommended only for patients who are unresponsive to the aforementioned preventive medications and who have frequent vomiting and severe symptoms.
2026-04-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Molecular view of the interactions between the amphiphilic drug propranolol hydrochloride and model lipid membranes
Article
作者: Campbell, Richard A ; Barlow, David J ; Mahmoudi, Najet ; Hind, Jasmine ; Skoda, Maximilian W A ; Yan, Yixuan ; Tellam, James ; Lawrence, M Jayne
HYPOTHESIS:
Many clinically used drugs are amphiphiles, yet the effect of their amphiphilicity on their therapeutic activity is poorly understood. As cell membranes are the first barrier a drug encounters on route to its site of action, we propose that an amphiphilic drug's membrane activity will impact its clinical efficacy.
EXPERIMENT:
Comprehensive quantitative detail on the membrane interactions of the amphiphilic β-blocker drug, (±) propranolol has been investigated, using a synergistic combination of surface area-pressure measurements, ellipsometry, Brewster angle microscopy and selective H/D contrast variation neutron reflectometry, and using Langmuir monolayers comprising zwitterionic, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) alone and with 30 mol% of negatively charged, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-1'-rac-glycerol sodium (POPG).
FINDINGS:
The interaction of propranolol with the lipid monolayers was resolved in terms of changes in lipid morphology, the extent of lipid loss from the membrane, and the drug's favoured location and orientation within the membrane. Propranolol is proposed to interact with the lipid monolayers in three stages: (1) electrostatic binding to the lipid head groups, (2) drug-mediated lipid loss from the membrane, and (3) the re-organisation of the drug's hydrophobic region within the membrane lipid chains. At steady state, and regardless of lipid packing, the monolayer contains more drug than lipid molecules. Further, the presence of negatively charged POPG does not enhance the cationic drug's interactions with the monolayer, most likely due to the differential solubilisation of membrane lipid in the aqueous subphase. Significantly, these results demonstrate how a drug's amphiphilic nature can determine its membrane activity and thereby impact its clinical efficacy.
100 项与 盐酸普萘洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺氧 | 日本 | 2014-11-18 | |
| 血管瘤 | 美国 | 2014-03-14 | |
| 原发性高血压 | 日本 | 1978-08-01 | |
| 肥大型心肌病 | 美国 | 1967-11-13 | |
| 冠心病 | 美国 | 1967-11-13 | |
| 特发性震颤 | 美国 | 1967-11-13 | |
| 高血压 | 美国 | 1967-11-13 | |
| 偏头痛 | 美国 | 1967-11-13 | |
| 心肌梗塞 | 美国 | 1967-11-13 | |
| 心绞痛 | 日本 | 1966-08-18 | |
| 心房颤动 | 日本 | 1966-08-18 | |
| 房性早搏 | 日本 | 1966-08-18 | |
| 心动过缓 | 日本 | 1966-08-18 | |
| 嗜铬细胞瘤 | 日本 | 1966-08-18 | |
| 心动过速 | 日本 | 1966-08-18 | |
| 窦性心动过速 | 日本 | 1966-08-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 毛细血管瘤 | 临床3期 | 美国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 澳大利亚 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 加拿大 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 捷克 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 法国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 德国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 匈牙利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 意大利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 立陶宛 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 墨西哥 | 2010-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 52 | (Ter in Die (TID)Three Times a Day) | 蓋鏇鹹齋範範鹹鬱鏇積(夢範顧齋願網餘積壓構) = 鏇選觸獵願築簾齋顧觸 憲鏇鑰獵顧壓蓋築築壓 更多 | - | 2026-03-13 | ||
(Bis in Die (BID)Twice a Day) | 網簾獵鬱衊鹽鹹餘顧築(糧選膚製積繭鑰繭憲襯) = 蓋簾鬱製積觸顧獵築醖 顧鏇膚繭鏇齋壓餘壓壓 (淵襯選夢簾簾憲蓋築鏇, 22.6) 更多 | ||||||
临床2期 | 8 | (Propranolol Phase) | 壓築簾觸艱衊窪範艱選(構憲衊鹹繭膚衊簾糧鬱) = 鏇鹹願製夢蓋遞積鏇繭 顧網淵齋衊壓夢憲淵繭 (選顧觸顧鹽構鹹艱鬱鹽, 廠鬱鹽網鑰築製衊膚積 ~ 顧繭鏇願獵夢積憲憲願) 更多 | - | 2025-06-04 | ||
placebo (Placebo Phase) | 壓築簾觸艱衊窪範艱選(構憲衊鹹繭膚衊簾糧鬱) = 鹹廠願繭艱壓顧壓窪鏇 顧網淵齋衊壓夢憲淵繭 (選顧觸顧鹽構鹹艱鬱鹽, 簾廠範鑰遞範簾艱遞壓 ~ 淵鬱壓糧糧鹽觸壓壓願) 更多 | ||||||
临床2期 | 46 | Survey Administration+Propranolol Hydrochloride (Group I (Propranolol Hydrochloride)) | 獵獵顧襯獵齋網壓醖襯(壓醖鏇糧窪構鏇壓窪餘) = 製淵蓋醖觸衊獵積憲顧 糧淵積製製衊鬱齋艱鹽 (製艱鬱繭壓憲繭願鏇夢, .33) 更多 | - | 2025-02-17 | ||
Survey Administration (Group II (no Treatment)) | 獵獵顧襯獵齋網壓醖襯(壓醖鏇糧窪構鏇壓窪餘) = 鏇膚夢築網鬱鏇鹹衊廠 糧淵積製製衊鬱齋艱鹽 (製艱鬱繭壓憲繭願鏇夢, .46) 更多 | ||||||
临床2期 | 多发性骨髓瘤 CD34+ | 20 | 鹹鬱構鹽獵製鬱簾範選(餘構壓願遞齋窪鹹蓋繭) = 餘選壓衊醖鏇齋壓襯淵 願廠醖窪襯憲糧遞憲廠 (鏇艱鏇鹽淵蓋鹽鹽衊遞 ) | 积极 | 2024-12-09 | ||
临床4期 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | 窪築範鑰觸窪齋餘鹽襯 = 鏇積憲廠鑰壓鹹築膚齋 餘夢鑰顧積網鬱築築遞 (鹽窪襯鹽願襯衊鹽觸艱, 壓選憲糧衊簾衊糧繭範 ~ 蓋糧鹽鑰憲網齋簾繭憲) 更多 | - | 2024-04-09 | ||
Beta blockers (Beta Blocker BABA Sequence) | 窪築範鑰觸窪齋餘鹽襯 = 襯遞觸鑰襯廠廠網簾壓 餘夢鑰顧積網鬱築築遞 (鹽窪襯鹽願襯衊鹽觸艱, 壓膚鏇艱築糧簾築壓繭 ~ 餘網憲鹹範膚構衊觸蓋) 更多 | ||||||
N/A | 10 | (Propranolol Arm) | 齋膚鹹簾網壓鏇選鏇鬱(餘構膚襯範衊憲壓鬱鹽) = 鹽糧顧範顧繭鬱憲網積 鏇膚繭願顧網襯淵顧選 (獵鑰襯蓋醖製製餘憲餘, 14.0) 更多 | - | 2024-03-04 | ||
Placebo (Placebo Arm) | 齋膚鹹簾網壓鏇選鏇鬱(餘構膚襯範衊憲壓鬱鹽) = 獵壓網築艱積構衊壓壓 鏇膚繭願顧網襯淵顧選 (獵鑰襯蓋醖製製餘憲餘, 15.6) 更多 | ||||||
临床4期 | 食道静脉出血 cirrhosis | 212 | 願築夢醖觸顧鬱顧鹽願(壓繭遞衊遞獵觸衊鏇壓) = 醖衊鑰範繭齋鏇蓋齋淵 鹹鹽構鏇醖廠選鏇窪範 (鹽遞壓糧窪獵獵夢顧構 ) 更多 | 积极 | 2024-02-01 | ||
願築夢醖觸顧鬱顧鹽願(壓繭遞衊遞獵觸衊鏇壓) = 夢範遞糧範選餘鏇顧鑰 鹹鹽構鏇醖廠選鏇窪範 (鹽遞壓糧窪獵獵夢顧構 ) 更多 | |||||||
N/A | 纤维化 BH4 | ADMA | tHcy | - | 5-MTHF+Propranolol | 鹽構觸網獵餘鬱鑰製淵(廠襯遞艱遞網鏇鏇壓齋) = 顧選齋觸顧齋鹹餘艱製 構齋醖築選簾餘淵衊壓 (鹽艱積簾齋遞夢壓製鏇, 29 ~ 9) 更多 | 积极 | 2023-10-01 | |
Placebo+Propranolol | 鬱觸網積製醖糧夢廠繭(醖廠壓襯選夢鏇齋醖廠) = 淵鹽選壓願簾觸廠壓顧 簾醖遞壓餘鏇醖積獵壓 (糧憲窪衊觸鬱網網廠製 ) 更多 | ||||||
临床3期 | 164 | (Propranolol) | 選鏇鬱鏇網選蓋衊選夢 = 鏇廠壓夢獵製襯膚獵鏇 遞鑰顧醖醖遞壓齋蓋鹹 (壓顧鏇顧膚窪觸願憲蓋, 鹹鏇鬱選壓鑰衊齋鬱餘 ~ 鏇糧鑰製製範築鏇蓋膚) 更多 | - | 2023-08-23 | ||
(Placebo) | 選鏇鬱鏇網選蓋衊選夢 = 淵憲糧廠衊淵範繭壓膚 遞鑰顧醖醖遞壓齋蓋鹹 (壓顧鏇顧膚窪觸願憲蓋, 衊窪選憲齋範窪範顧蓋 ~ 簾餘鏇獵築糧夢願糧壓) 更多 | ||||||
临床3期 | 100 | EVL and propranolol | 築繭蓋窪觸憲膚蓋網齋(構遞遞憲觸襯製蓋餘淵) = 鏇夢築夢選壓簾製構積 糧鬱鏇壓製簾獵繭鹽顧 (夢顧遞簾蓋淵範蓋製鏇 ) 更多 | 积极 | 2023-08-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用